191 related articles for article (PubMed ID: 36151051)
1. Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation.
Perretti M; Dalli J
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():449-469. PubMed ID: 36151051
[TBL] [Abstract][Full Text] [Related]
2. Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases.
Perucci LO; Sugimoto MA; Gomes KB; Dusse LM; Teixeira MM; Sousa LP
Expert Opin Ther Targets; 2017 Sep; 21(9):879-896. PubMed ID: 28786708
[TBL] [Abstract][Full Text] [Related]
3. Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7).
Tavares LP; Melo EM; Sousa LP; Teixeira MM
Semin Immunol; 2022 Jan; 59():101601. PubMed ID: 35219595
[TBL] [Abstract][Full Text] [Related]
4. Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy.
Xu R; Weber MC; Hu X; Neumann PA; Kamaly N
Semin Immunol; 2022 Nov; 61-64():101664. PubMed ID: 36306664
[TBL] [Abstract][Full Text] [Related]
5. Annexin A1 and resolution of inflammation: tissue repairing properties and signalling signature.
Gobbetti T; Cooray SN
Biol Chem; 2016 Oct; 397(10):981-93. PubMed ID: 27447237
[TBL] [Abstract][Full Text] [Related]
6. Specialized proresolution mediators in the bladder: annexin-A1 normalizes inflammation and bladder dysfunction during bladder outlet obstruction.
Hughes FM; Harper SN; Nosé BD; Allkanjari A; Zheng MT; Jin H; Purves JT
Am J Physiol Renal Physiol; 2021 Oct; 321(4):F443-F454. PubMed ID: 34396790
[TBL] [Abstract][Full Text] [Related]
7. Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology.
Perretti M; Godson C
Br J Pharmacol; 2020 Oct; 177(20):4595-4600. PubMed ID: 32954491
[TBL] [Abstract][Full Text] [Related]
8. Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseases.
Vago JP; Tavares LP; Riccardi C; Teixeira MM; Sousa LP
Biomed Pharmacother; 2021 Jan; 133():111033. PubMed ID: 33378946
[TBL] [Abstract][Full Text] [Related]
9. Annexin A1 promotes timely resolution of inflammation in murine gout.
Galvão I; Vago JP; Barroso LC; Tavares LP; Queiroz-Junior CM; Costa VV; Carneiro FS; Ferreira TP; Silva PM; Amaral FA; Sousa LP; Teixeira MM
Eur J Immunol; 2017 Mar; 47(3):585-596. PubMed ID: 27995621
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers.
Sajid S; Zariwala MG; Mackenzie R; Turner M; Nell T; Bellary S; Renshaw D
Nutrients; 2022 Jun; 14(11):. PubMed ID: 35684160
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury.
Ansari J; Kaur G; Gavins FNE
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29659553
[TBL] [Abstract][Full Text] [Related]
12. Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19?
Sousa LP; Pinho V; Teixeira MM
Br J Pharmacol; 2020 Sep; 177(17):3898-3904. PubMed ID: 32557557
[TBL] [Abstract][Full Text] [Related]
13. Resolution of inflammation in neuromyelitis optica spectrum disorders.
Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
[TBL] [Abstract][Full Text] [Related]
14. The Multifaceted Role of Annexin A1 in Viral Infections.
Resende F; Araújo S; Tavares LP; Teixeira MM; Costa VV
Cells; 2023 Apr; 12(8):. PubMed ID: 37190040
[TBL] [Abstract][Full Text] [Related]
15. Inflammation resolution and specialized pro-resolving lipid mediators in chronic rhinosinusitis.
Robinson PZ; Frank DN; Ramakrishnan VR
Expert Rev Clin Immunol; 2023; 19(8):969-979. PubMed ID: 37392068
[TBL] [Abstract][Full Text] [Related]
16. Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.
Perretti M; Dalli J
Br J Pharmacol; 2009 Oct; 158(4):936-46. PubMed ID: 19845684
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of pro-resolving mediators in diabetic kidney disease.
Vartak T; Godson C; Brennan E
Adv Drug Deliv Rev; 2021 Nov; 178():113965. PubMed ID: 34508793
[TBL] [Abstract][Full Text] [Related]
18. Pro-inflammatory and pathogenic properties of Annexin-A1: the whole is greater than the sum of its parts.
D'Acquisto F; Piras G; Rattazzi L
Biochem Pharmacol; 2013 May; 85(9):1213-8. PubMed ID: 23435354
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Annexin A1-FPR2/ALX pathway for host-directed therapy in dengue disease.
Costa VV; Sugimoto MA; Hubner J; Bonilha CS; Queiroz-Junior CM; Gonçalves-Pereira MH; Chen J; Gobbetti T; Libanio Rodrigues GO; Bambirra JL; Passos IB; Machado Lopes CE; Moreira TP; Bonjour K; Melo RCN; Oliveira MAP; Andrade MVM; Sousa LP; Souza DG; Santiago HDC; Perretti M; Teixeira MM
Elife; 2022 Mar; 11():. PubMed ID: 35293862
[TBL] [Abstract][Full Text] [Related]
20. Annexin A1: shifting the balance towards resolution and repair.
Leoni G; Nusrat A
Biol Chem; 2016 Oct; 397(10):971-9. PubMed ID: 27232634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
